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Running title: Pru:Δcdpk2-based vaccine for Toxoplasma gondii. 
 
Short summary: We have demonstrated the development of a balanced Th1/Th2 immune 
response in mice following a vaccination regime using Toxoplasma gondii Pru:Δcdpk2 mutant. 
Vaccinated mice survived the challenge with homologous and heterologous strains, and were 
protected against different forms of toxoplasmosis. 
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Abstract 
Background: 
The threat of Toxoplasma gondii infection in immunocompromised individuals and pregnant 
women necessitates the development of a safe and effective vaccine. Here, we examined the 
immune protection conferred by live-attenuated strain of T. gondii. 
Methods: 
We tested the efficacy of intraperitoneal vaccination using 500 Ca2+-dependent protein kinase 2 
(cdpk2)-deficient tachyzoites of T. gondii Pru strain ag inst acute, chronic and congenital 
toxoplasmosis in mice. The kinetics of antibody response, cytokines, and other quantifiable 
correlates of protection against T. gondii infection were determined. 
Results: 
Vaccination with Pru:Δcdpk2 induced a high level of anti-T. gondii IgG titer, Th1 response at 28 
days post-vaccination (dpv), and mixed Th1/Th2 response at 70 dpv. All vaccinated mice 
survived a heterologous challenge with 1000 tachyzoites of RH or ToxoDB#9 (PYS or TgC7) 
strains. Also, vaccination protected against homologous infection with 20 T. gondii Pru cysts, and 
improved pregnancy outcome by reducing parasite cyst load in the brain, maintaining litter size 
and body weight of pups born to vaccinated dams challenged with 10 Pru cysts compared to 
pups born to unvaccinated dams.  
Conclusion: 
The use of T. gondii Pru:Δcdpk2 mutant strain represents a promising approach to protection 
against acute, chronic and congenital toxoplasmosis in mice.  
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INTRODUCTION 
Toxoplasma gondii is an obligate intracellular protozoan parasite and the causative agent of 
toxoplasmosis, a prevalent disease that can affect all warm-blooded animals and humans [1-3]. 
Infections in immunocompromised individuals, such as organ transplant patients and AIDS 
patients, can cause severe or even a fatal outcome [1-3]. Primary infection during pregnancy can 
cause neonatal malformations, miscarriage, chorioretinitis, blindness, mental retardation and 
hydrocephalus in the infected fetus [3-6]. Current treatments of toxoplasmosis are challenged by 
side effects of current medications [7] and the occurrence of drug-resistant strains [8]. New 
approaches are therefore needed to develop more effective interventions for better prevention 
and control of toxoplasmosis.  
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Vaccination using live-attenuated strains is promising because it can trigger a protective 
humoral and cellular immunity through simulating natural infection without leading to the 
disease [9,10]. A commercially available vaccine, Toxovax®, developed from T. gondii S48 strain, 
is licensed for use in sheep and goats to prevent abortion in the UK, New Zealand, France, and 
Ireland [11]. Attenuation of the virulence of T. gondii through deletion of certain genes has been 
achieved in several studies [12-18]. The Mic1-3KO RH strain, lacking mic1 and mic3 micronemal 
proteins protected mice against chronic and congenital toxoplasmosis [12] and reduced T. 
gondii-induced abortion and tissue cyst burden in lambs born to vaccinated ewes [13]. Recently, 
we have shown that immunization of Kunming mice with RH:ΔGRA17 conferred significant 
protection against acute, chronic and congenital T. gondii infection [14]. Other groups have 
shown that uracil auxotrophic mutants elicited a protective immunity against acute and chronic 
T. gondii infection in mice [15-18].  
Toxoplasma gondii possesses 14 Ca2+-dependent protein kinases (CDPKs), which play 
important roles in the parasite’s motility, colonization, replication and egress [19-23]. Recently, 
cdpk2 has been shown to play a role in the regulation of parasite amylopectin synthesis and 
degradation [23]. Disruption of cdpk2 induced abnormal accumulation of massive amylopectin 
granules in T. gondii tachyzoites and in the vacuolar space of the residual bodies, together with 
complete ablation of cyst formation [23]. Because of its inability to establish chronic infection in 
mice [23], Pru:Δcdpk2 mutant has emerged as an attractive candidate to produce a safe and 
efficacious vaccine [24].  
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In this study, we determined the protective efficacy of a live attenuated T. gondii Pru mutant 
with a target deletion of cdpk2 (designated Pru:Δcdpk2), delivered intraperitoneally. Kunming 
mice vaccinated with 500 Pru:Δcdpk2 tachyzoites developed a protective immune response 
against acute, chronic and congenital toxoplasmosis. We also explored the possibility that if 
disruption of cdpk2 in RH strain impairs its virulence in mice, then a RH:Δcdpk2 mutant might be 
a potential vaccine candidate. 
 
MATERIALS AND METHODS 
Mice 
Eight-week-old Kunming mice were obtained from Laboratory Animal Center of Lanzhou 
University. All procedures were approved by the Animal Ethics Committee of Lanzhou 
Veterinary Research Institute, Chinese Academy of Agricultural Sciences. Kunming mice were 
used in this study because of their susceptibility to acute and chronic T. gondii infection [14, 
25-27] and because of their ability to produce more pups per litter, to better assess protection 
against congenital infection, compared with BALB/c and C57BL/6 mice [28].  
 
Parasites  
Tachyzoites of T. gondii type I (RH, PYS and TgC7), type II (Pru), and mutant strains RH:Δcdpk2 
and Pru:Δcdpk2 were maintained in human foreskin fibroblast cultures, as previously described 
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[22, 29]. Cysts of T. gondii Pru strain were isolated from brain homogenates of Kunming mice as 
previously described [25-27].  
 
Disruption of CDPK2 by CRISPR-Cas9 system 
CRISPR-Cas9 system was used to knockout cdpk2 gene as previously described [30]. Guide RNA 
and primers used in the study to generate mutant Δcdpk2 strains are listed in Supplementary 
Table S1. The pattern of in vitro growth of tachyzoites of T. gondii Δcdpk2 deletion mutant was 
compared to wild type (WT) strain as previously described [14].  
 
Virulence of Mutants Versus Wild-type Strains in Mice 
Freshly harvested 200 tachyzoites of RH strain or RH:Δcdpk2 mutant, or 1×105 tachyzoites of 
Pru strain or Pru:Δcdpk2 mutant were injected intraperitoneally (i.p.) into mice (10 
mice/group/parasite strain). These mice were monitored daily for the development of clinical 
signs of acute illness and mortality was recorded until all mice died. 
 
Vaccination of Mice 
In these experiments, the efficacy of Pru:Δcdpk2 mutant strain in conferring protective immunity 
was evaluated against acute, chronic, and congenital T. gondii infections (Supplementary Figure 
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S1). Mice were either vaccinated once with 500 freshly harvested Pru:Δcdpk2 tachyzoites or 
mock-vaccinated in a total of 200 µl PBS i.p. We used i.p. vaccination route because it can trigger 
both systemic and mucosal immune responses.  
 
Antibody Measurement Post-vaccination  
Serum samples were obtained at day 28 and 70 post-vaccination. Total IgG content and 
subclasses of IgG antibodies, IgG2a and IgG1 as indicators of Th1 and Th2 responses, 
respectively were tested by ELISA as described [14, 25-27].  
 
Vaccine-Induced Cytokine Production 
Mice were sacrificed seventy days post-vaccination (dpv) and single splenocyte suspensions 
were obtained as previously described [14, 25-27]. Splenocyte cultures were incubated in vitro 
with 10 µg/ml T. gondii soluble tachyzoite antigen (STAg) and supernatants were tested by 
ELISA for the presence of secreted cytokines IL-2 (24-h post-incubation), IL-10 (72-h 
post-incubation), IL-12 and IFN-γ (96-h post-incubation) in accordance with the manufacturer’s 
instructions (eBioscience® Bender MedSystems GmbH, Austria). 
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Seventy dpv, both vaccinated and age-matched naïve mice were challenged i.p. with 200 μl PBS 
containing 1,000 tachyzoites of RH, ToxoDB#9 (PYS or TgC7) strain to test efficacy against acute 
infection; or were inoculated orally with 20 Pru cysts to test efficacy against chronic infection. 
Strains of ToxoDB#9, the predominant genotype in China, have a comparable virulence to type I 
RH strain [31, 32]. Thus, it was sensible to determine whether immune responses induce by the 
Pru:Δcdpk2 mutant strain protects against infection with the local strains (TgC7 and PYS) of 
ToxoDB#9 genotype. It was also important to evaluate the ability of Pru:Δcdpk2 to confer 
protection against challenge with Pru strain, the predominant genotype during congenital 
infection in humans and sheep [33, 34]. The degree of illness and survival of all mice were 
observed daily for 35 days.  
Seven days post-infection (dpi), peritoneal fluid and serum samples collected from 
Pru:Δcdpk2-vaccinated mice infected with RH, non-vaccinated + RH infected mice, and 
non-vaccinated + uninfected mice were tested for Th1 cytokines (IFN-γ and IL-12) during acute 
infection by ELISA. For chronic infection, mice were euthanized at 35 dpi, and their brains were 
removed and individually homogenized in 1 ml of PBS. Brain cyst’s burden was assessed by 
examining dilutions of DBL-stained brain homogenates using a Zeiss wide-field epiﬂuorescence 
microscope with 10×objective, as described [14].  
Protection Against Congenital Transmission  
Female mice vaccinated with 500 Pru:Δcdpk2 tachyzoites were mated with male mice 70 dpv. 
Two female mice were housed in a cage with one male and every 12 h female mice were 
Protection against Acute and Chronic Infection 
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inspected for the presence of vaginal plugs. The day of presence of vaginal plug was designated 
day 1 of gestation. On day 12 of gestation, mice were infected orally with 10 T. gondii Pru cysts. 
Control mouse groups included: non-vaccinated uninfected mice (negative control), and 
non-vaccinated mice infected orally infected with 10 Pru cysts. The level of protection against 
congenital T. gondii infection was evaluated by analyzing litter size and survival rate of the 
naturally delivered pups at birth and 35-day old. The body weight of pups at 35-day old were 
also used to evaluate the protective efficacy. The level of maternal protection in Pru 
cysts-challenged dams and their pups was determined by quantifying the brain tissue cyst 
burden in surviving pups at 35 days of age, and in their dams at 30 days after delivery. Maternal 
splenocytes from pregnant mice challenged with 10 Pru cysts on day 12 of gestation were 
collected six days later. Splenocyte culture was stimulated with 10 µg/ml STAg and the level of 
Th1 (IFN-γ, IL-2, IL-12), and Th2 (IL-10) cytokines in vaccinated + infected mice, non-vaccinated 
+ infected mice, and non-vaccinated + uninfected mice was evaluated using ELISA, as described 
above. 
 
Statistical Analysis 
The differences in the level of cytokines, anti-T. gondii antibodies and parasite cysts’ burdens 
were compared using two-tailed, unpaired Student’s t-test (for comparing means between two 
groups) or one-way ANOVA analysis (for comparing means between ≥ three groups). The SD 
was derived from three independently performed experiments with three replicates per 
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experiment for the in vitro assays. Values of P < 0.05 were considered statistically significant. 
Mortality was determined by plotting survival curves of the different mouse groups stratified by 
T. gondii infection and vaccination status by Mantel–Cox log-rank test. 
 
RESULTS 
 
Deletion of cdpk2 gene in T. gondii RH and Pru Strains 
The cdpk2 gene was successfully knocked out in RH and Pru strains using CRISPR-Cas9 system. 
In both strains, the DHFR* was inserted into the gRNA-targeted coding sequence region through 
nonhomologous end joining (NHEJ) (Supplementary Figure S2A). Single, stable 
pyrimethamine-resistant clones were generated and verified by specific PCR method 
(Supplementary Figure S2B). Phenotypic characterization of RH:Δcdpk2 or Pru:Δcdpk2 
tachyzoites revealed abnormal morphology and excessive accumulation of granules at both the 
tachyzoites basal end and within the tachyzoites residual body, whereas tachyzoites of the WT 
RH and Pru strains appeared normal (Supplementary Figure S3). These results demonstrate that 
cdpk2 gene was successfully knocked out in the mutant RH and Pru strains. 
Disruption of cdpk2 does not affect virulence in mice 
Deletion of cdpk2 gene did not result in attenuation of the virulence of mutant RH or Pru strains, 
as indicated by the comparable survival rates of mice infected with the parental WT or mutant 
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strains (Supplementary Figure S4). In an effort to achieve the required level of immunogenicity 
of the attenuated Pru:Δcdpk2 strain, without inducing an excessive immune response or death in 
the vaccinated mice, we reduced the number of type II Pru:Δcdpk2 tachyzoites used in the 
vaccination experiments from 105 to 500 tachyzoites. Mice challenged with 500 Pru:Δcdpk2 
mutant tachyzoites survived and consistent with previous work [23], tissue cysts were not 
detected in the brain of mice challenged with 500 Pru:Δcdpk2 tachyzoites, but brain tissue cysts 
were detected in mice challenged with 500 WT Pru tachyzoites (data not shown). 
 
Humoral immune responses induced by vaccination 
The immunogenicity of Pru:Δcdpk2 was assessed by determination of specific anti-T. gondii IgG 
antibody titers and IgG isotypes in the serum of vaccinated mice at 28 and 70 dpv by 
quantitative ELISA. At day 28 post-vaccination, all vaccinated mice had seroconverted with a 
higher level of anti-T. gondii IgG antibodies compared with non-vaccinated mice. This level of IgG 
titer remained high at 70 dpv (Figure 1). These results suggest that Pru:Δcdpk2 induced a strong 
humoral response. We then tested whether a Th1 and Th2 response was elicited in the 
vaccinated mice by evaluating the levels of STAg-specific IgG subclasses, IgG2a and IgG1 
isotypes, respectively. Compared to non-vaccinated mice, the level of IgG2a was significantly 
higher in vaccinated mice at 28 and 70 dpv. The level of IgG1 was only increased in the 
vaccinated mice at 70 dpv, compared with non-vaccinated mice (Figure 1). These results suggest 
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that vaccination with Pru:Δcdpk2 in mice elicits a Th1-type immune response at 28 dpv and a 
mixed Th1/Th2 immune response at 70 dpv.  
 
Cytokine production after vaccination  
Cytokine production in splenocyte culture supernatants stimulated with STAg was assessed by 
ELISA at 70 dpv. The levels of Th1 type cytokines (IFN-γ, IL-2 and IL-12) were significantly 
higher than those in non-vaccinated mice. Also, the level of Th2 type cytokine (IL-10) was 
significantly higher than that of non-vaccinated mice (Figure 2). 
 
Pru:Δcdpk2 immunogenicity and potency for protection against acute infection 
Kunming mice were vaccinated with 500 Pru:Δcdpk2 tachyzoites, and 70 days later, challenged 
with 1,000 tachyzoites of T. gondii type I RH strain, or ToxoDB#9 (PYS or TgC7) strain. As 
expected, all non-vaccinated mice infected with 1,000 RH strain or ToxoDB#9 (PYS or TgC7) 
strains died within 10 days after infection, whereas all mice vaccinated survived regardless of 
the challenging strains (Figure 3). We further analyzed Th1 cytokines (IL-12 and IFN-γ) in the 
serum and peritoneal fluids at 7 days after infection. Significantly elevated levels of IL-12 and 
IFN-γ were found in the non-vaccinated + RH infected mice, while only modestly elevated levels 
of the same cytokines was observed in Pru:Δcdpk2 vaccinated + RH infected mice (Figure 4).  
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Protection against chronic infection 
The protective efficacy of vaccination with Pru:Δcdpk2 against chronic infection was 
investigated in Kunming mice at 70 dpv. All Pru:Δcdpk2-vaccinated mice survived infection with 
20 T. gondii Pru parasite cysts, whereas only 40% of non-vaccinated infected mice survived 
(Figure 5A). At 35 days post-challenge, parasite cyst burden in the brain of survived 
Pru:Δcdpk2-vaccinated compared with non-vaccinated mice was determined. Non-vaccinated 
mice challenged with 20 Pru cysts had 4296 ± 687 cysts per brain, whereas 
Pru:Δcdpk2-vaccinated mice challenged with the same number of Pru cysts had significantly 
fewer cysts per brain (78 ± 48 cysts/brain) (P < 0.001; Figure 5B). 
 
Protection Against Congenital Toxoplasmosis 
Pregnant mice were orally challenged with 10 T. gondii Pru cysts on day 12 of gestation, the 
litter size and body weight of the neonates were determined. The cyst burden in the brain of 
neonates and dams was evaluated. The litter size and survival of pups of Pru:Δcdpk2-vaccinated 
+ Pru cysts infected dams, was similar to that of non-vaccinated uninfected mice (Figure 6A). 
Body weight of neonates born to Pru:Δcdpk2-vaccinated + Pru cysts infected dams was similar to 
neonates born to non-vaccinated uninfected dams (Figure 6B). In contrast, the litter size and 
body weight of pups of non-vaccinated + Pru cysts infected mice were significantly lower when 
compared to that of non-vaccinated uninfected mice, or Pru:Δcdpk2-vaccinated + Pru cysts 
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infected mice. The brain cyst burden in the neonates was determined at day 35 post-partum. The 
average brain cyst number in all neonates (n = 19) born to non-vaccinated + Pru cysts infected 
dams was 919 ± 339. In contrast, 41.4% (24 out of 58) of neonates born to 
Pru:Δcdpk2-vaccinated + Pru cysts infected dams had an average brain cyst number of (60 ± 33). 
Interestingly, examination of the brain of 58.6% (34 of 58) of neonates born to vaccinated + 
infected dams revealed no cysts. The brain cyst burden in dams was also determined at day 30 
post-partum. The average brain cyst number was significantly higher in non-vaccinated + Pru 
cysts infected dams (3287 ± 569 cysts/brain) than in that of Pru:Δcdpk2-vaccinated + Pru cysts 
infected dams (77 ± 58 cysts/ brain).  
 
Immune Responses to Infection During Pregnancy 
The levels of T. gondii-specific Th1 (IFN-γ, IL-12, IL-2) and Th2 (IL-10) cytokines from 
Pru:Δcdpk2-vaccinated + Pru cysts infected mice were significantly higher compared with those 
in non-vaccinated + Pru cysts infected mice, and non-vaccinated uninfected mice (P < 0.001; 
Figure 7). However, the difference in the cytokines levels between non-vaccinated + Pru cysts 
infected, and non-vaccinated uninfected mice were not statistically significant (P > 0.05). 
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A highly effective vaccine against toxoplasmosis is urgently required, with leading vaccination 
strategies targeting both horizontal transmission and vertical transmission from pregnant dams 
to their offspring. Previous study has shown that cdpk2 is essential for the development of viable 
T. gondii tissue cysts, as cdpk2-deficient parasite strains failed to form cysts in the brain of mice 
[23]. Based on this observation, we inferred that cdpk2-deficient T. gondii might be a promising 
live-attenuated vaccine to prevent toxoplasmosis. In the present study, cdpk2 was successfully 
disrupted in T. gondii RH and Pru strains using CRISPR-Cas9 method, and the mutant strains 
exhibited the anticipated morphological abnormalities, and no parasite cyst was detected in the 
brain of mice challenged with Pru:Δcdpk2 tachyzoites, which was consistent with previous study 
[23].  
Our results showed that deletion of cdpk2 gene did not result in the attenuation of the 
virulence of RH or Pru strains, as indicated by the comparable survival rates of mice infected 
with the parental WT (RH or Pru) or mutant (RH:Δcdpk2 or Pru:Δcdpk2) strains. A high dose 
(105) of Pru:Δcdpk2 tachyzoites caused mice death in 11 days, however all mice infected with 
the same strain, but with a smaller dose (500) survived and no parasite cyst was detected in 
their brain. Therefore, 500 Pru:Δcdpk2 tachyzoites were used in all subsequent experiments as 
the vaccination dose because it exhibited the type of balance between safety and high 
immunogenicity that should be expected of a promising live-attenuated vaccine strain.  
Consistent with other attenuated T. gondii vaccines, vaccination with Pru:Δcdpk2 induced a 
high level of anti-T. gondii IgG antibodies in mice [12-18]. These specific IgG antibodies can 
neutralize the attachment of T. gondii and limit its ability to establish infection [35-38]. 
DISCUSSION 
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Pru:Δcdpk2-vaccinated mice also developed a sequential Th1 and mixed Th1/Th2-type immune 
response, as indicated by the high level of Th1 immunity (IgG2a) at day 28 post-vaccination; and 
the elevation of Th2 protective (IgG1) level at day 70 dpv when compared to that in 
non-vaccinated mice. The high level of IgG2a and IgG1 in Pru:Δcdpk2-vaccinated mice was 
substantiated by high levels of Th1 cytokines (IFN-γ, IL-2 and IL-12) and Th2 cytokines (IL-10) 
at 70 dpv. Indeed, these immune response induced by Pru:Δcdpk2 vaccination completely 
protected mice (i.e. 100% survival rate) post-challenge with RH, or ToxoDB#9 (PYS or TgC7) 
strain, whereas non-vaccinated mice died within 10 dpi. In addition, Pru:Δcdpk2 significantly 
reduced the development of chronic toxoplasmosis. The parasite cysts were significantly 
reduced in the brain of vaccinated mice after infection with 20 cysts of T. gondii Pru strain 
compared with non-vaccinated + Pru cysts infected mice. In our study, Th1 cytokines from the 
non-vaccinated + RH-infected mice was significant higher than that from the Pru:Δcdpk2 
vaccinated + RH-infected mice, indicating that vaccination with Pru:Δcdpk2 may have 
down-regulated Th1 response and reduced the severe inflammatory response that accompanies 
acute T. gondii infection [39-42].  
Th1-type cytokine response with high level of IFN-γ, IL-2 and IL-12, are needed to limit 
congenital transmission and to protect pregnant mice against T. gondii infection [43-46]. 
However, Th1-type immune response can be detrimental to pregnancy and potentially 
deleterious for the conceptus [43, 44]. Thus, a balanced Th1/Th2 immune response detected at 
day 70 post-vaccination seems to contribute to the observed successful pregnancy outcomes; 
because unsuccessful pregnancies were observed at day 28 post-vaccination (data not shown) 
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where Th1 response was dominating (Figure 1). Therefore, the high level of Th2-related 
anti-inflammatory cytokine, IL-10, which suppresses the production of Th1 cytokines (IFN-γ and 
IL-12) detected in Pru:Δcdpk2-vaccinated pregnant mice infected with Pru cysts on day 12 of 
gestation (Figure 7) may have contributed to better pregnancy outcomes when compared to 
non-vaccinated + Pru-infected pregnant mice. Higher IL-10 levels appear to play a role in 
protection against infection, because IL-10-deficient mice died during acute T. gondii infection 
due to a strong Th1 inflammatory response [47]. Previous studies showed that pregnancy 
outcomes can be improved in T. gondii-infected mice by administration of recombinant IL-10 
and can be worsened in IL-10-deficient mice [48]. Despite the inhibitory effect of maternal and 
fetal Th2 polarized immune response that occurs during pregnancy on Th1 cytokine production, 
vaccination seems to elicit a protective immune response that enabled the pregnant mice to 
control the infection. These results show that vaccination of mice with Pru:Δcdpk2 achieved a 
critical balance between Th1 and Th2 responses for optimal control of infection, while 
minimizing overt inflammation and severe pathology. 
Although the immune responses induced by Pru:Δcdpk2 vaccination cannot completely 
block the vertical transmission, a statistically lower brain cyst burden was observed in pups 
from Pru:Δcdpk2-vaccinated + Pru-infected dams, compared to pups of non-vaccinated + 
Pru-infected dams. In addition, there were significantly less numbers of brain cysts in 
Pru:Δcdpk2-vaccinated + Pru-infected dams than in non-vaccinated + Pru-infected dams. Also, 
neonates born to Pru:Δcdpk2-vaccinated + Pru-infected dams had similar body weights to 
neonates born to non-vaccinated + uninfected mice. These results indicate that vaccination with 
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Pru:Δcdpk2 can confer significant protection against subsequent oral infection with Pru cysts 
during the second trimester of gestation. Unexpectedly, infection with T. gondii Pru strain at 12 
days of gestation failed to elicit more cytokines in non-vaccinated + Pru-infected mice, compared 
with non-vaccinated + uninfected mice (Figure 7). At present, the reason for this observation is 
unknown. However, it is possible that the time elapsed after infection was not long enough to 
elicit a detectable level of cytokines nor to induce potent CD8+ T cell responses without prior 
antigenic stimulation.  
In conclusion, data reported in this study demonstrate that a single i.p. vaccination of 500 
Pru:Δcdpk2 tachyzoites provides cross-protection against homologous and heterologous 
challenge with multiple T. gondii strains of the same and different genotypes in mice. Pru:Δcdpk2 
strain generated an immune response, which improved the survival rate and reduced parasite 
cyst burden in the brain of the vaccinated mice. Strong protection against congenital 
toxoplasmosis was demonstrated by a significant reduction in the brain tissue cyst burden in the 
pups and their dams, along with improvement in the body weight and survival rate of pups born 
to vaccinated dams compared with non-vaccinated dams. Given the potential efficacy of 
Pru:Δcdpk2 live-attenuated vaccine, the data generated in Kunming mice merit further 
exploration and should be evaluated in larger animals, such as sheep. 
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Figures legends 
 
Figure 1: Humoral response and antibody isotype profile in the serum of mice vaccinated 
with Pru:Δcdpk2 by intraperitoneal route. Levels of IgG and IgG subclass (IgG2a and IgG1) 
antibodies were evaluated in the sera of mice at 28 and 70 days after Pru:Δcdpk2-vaccination 
compared to non-vaccinated mice. The patterns of IgG2a to IgG1 show the induction of a Th1 
immune response at day 28 post-vaccination, followed by a mixed Th1/Th2 immune response at 
day 70 post-vaccination. Results are expressed as mean of OD450 ± SD. Significance compared 
with control (uninfected + non-vaccinated) mice: ***P < 0.001. 
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Figure 2: Levels of Th1 and Th2 cytokines produced by splenocytes culture of 
Pru:Δcdpk2-vaccinated mice. Spleen cells from six mice were obtained 70 days 
post-vaccination and stimulated in vitro with 10 µg/ml soluble T. gondii tachyzoite antigen 
(STAg). Cell-free supernatants were harvested and evaluated for Th1 (IFN-γ, IL-2 and IL-12) and 
Th2 (IL-10) cytokines using ELISA. Significance compared with control (uninfected + 
non-vaccinated) mice: **P < 0.01, ***P < 0.001. 
 
Figure 3: Protection of mice against acute Toxoplasma gondii infection. Survival curves of 
Pru:Δcdpk2-vaccinated mice, challenged intraperitoneally with 103 tachyzoites of RH, PYS, or 
TgC7 strains 70 days post-vaccination. The survival of mice was monitored for 35 days. A 
Log-rank (Mantel–Cox) test showed significant difference in the survival rates between 
vaccinated + infected groups compared to non-vaccinated+ infected groups (P = 0.003). All mice 
in the vaccinated groups remained alive at day 35 after infection, but all mice in the 
non-vaccinated groups died between day 7 and 10 after infection. In addition to the separate 
curves that show the difference in the survival rate between vaccinated and non-vaccinated 
mouse groups infected with RH, PYS, or TgC7 strains (A–C), the overall survival rates in all 
vaccinated mouse groups compared with the non-vaccinated mouse groups were combined in 
one graph (D). 
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Figure 4: Pro-inflammatory cytokines produced by Pru:Δcdpk2-vaccinated mice after 
infection with Toxoplasma gondii RH. Mice were challenged with 103 RH tachyzoites 70 days 
post-vaccination and levels of IFN-γ and IL-12 in the serum and peritoneal washes were 
assessed by ELISA at 7 days post infection. Highest levels of pro-inflammatory cytokines were 
found in the non-vaccinated infected mice. Significance compared with uninfected and 
non-vaccinated control mice: **P < 0.01, ***P < 0.001. 
 
Figure 5: Vaccination with Pru:Δcdpk2 promoted survival and reduced brain cyst’s 
burden after infection. (A) Survival curves following challenge of Pru:Δcdpk2-vaccinated mice 
with 20 cysts of T. gondii Pru strain, compared with non-vaccinated mice, 70 days 
post-vaccination. The survival of mice was monitored for 35 days. A Log-rank (Mantel–Cox) test 
demonstrated a significant difference between the vaccinated and non-vaccinated groups (P = 
0.0001). (B) Cyst burden in the brain of mice that survived to 35 days after challenge 
(Pru:Δcdpk2-vaccinated + Pru-infected mice vs non-vaccinated + Pru-infected mice). Data points 
indicate means ± SD. ***P < 0.001 
 
Figure 6: Protection of mice against type II Pru cyst infection on day 12 of 
gestation. (A) The litter size and survival of pups from non-vaccinated uninfected mice, 
non-vaccinated + Pru-infected mice, and Pru:Δcdpk2-vaccinated + Pru-infected mice was 
assessed at birth and 35 days after birth. (B) The average body weight of 35-day-old pups. Data 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy211/4969761
by guest
on 17 April 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
points indicate means ± SD. Significance compared with control (uninfected + non-vaccinated) 
mice: ***P < 0.001. 
 
Figure 7: Profile of Toxoplasma gondii-specific Th1 and Th2 cytokines 
in Pru:Δcdpk2-vaccinated mice after infection with Pru cysts. Vaccinated, pregnant mice 
were infected with T. gondii Pru cysts 12 days of gestation and spleen cells were collected 6 days 
after infection. Splenocyte culture was stimulated with 10 µg/ml T. gondii soluble tachyzoite 
antigen. Cell-free supernatants were evaluated for Th1 (INF-γ, IL-2 and IL-12) and Th2 (IL-10). 
Cytokine concentrations represent mean ± SD after subtraction of background control values 
with medium only. Significance compared with control (uninfected + non-vaccinated) mice: 
***P < 0.001. 
 
Supplementary material 
Supplementary TABLE S1: General information of guide RNA (gRNA) and primers used in 
this study 
 
Supplementary Figure S1: Schematic illustration of the vaccination regimens. Experimental 
overview of the present investigation from vaccination of Kunming mice with 500 
Pru:Δcdpk2 tachyzoites (A), assessment of immune response in the serum of vaccinated mice prior to 
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infection (B) to the evaluation of the immunogenicity and protection of vaccination against acute 
infection (C), chronic infection (D) and congenital infection (E). For simplicity, only experiments that 
involved the vaccinated and infected groups are shown. More details about other experimental mouse 
groups and controls can be found in “Materials and Methods.” Abbreviations: i.p., intraperitoneal; dpi, 
days post infection. 
 
Supplementary Figure S2: Generation of cdpk2 mutant strains using CRISPR-Cas9. A. 
Schematic illustration of gene disruption by insertion of a pyrimethamine-resistant DHFR 
(DHFR*) cassette into the coding sequence of cdpk2 gene. B. KO-cdpk2-F and KO-cdpk2-R 
primers were used to amplify the small fragment around the gRNA. Small fragment was lost due 
to insertion of the larger fragment created by insertion of DHFR* under short extension times.  
 
Supplementary Figure S3: Morphological characteristics of Toxoplasma gondii Δcdpk2 
mutant strains growing in human foreskin fibroblast cells. Parasite morphology was 
examined by indirect fluorescence staining using anti-SAG1 antibody that labels the extracellular 
coat of the parasite. The arrows indicate the site of amylopectin accumulation in RH:Δcdpk2 and 
Pru:Δcdpk2 strains. Tachyzoites of wild-type RH and Pru strains appeared normal. 
 
Supplementary Figure S4: Comparative virulence between Toxoplasma gondii wild-type 
and cdpk2 mutant RH and Pru strains in mice. The survival rate of Kunming mice infected 
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with wild-type (WT) RH and Pru strains were compared to their respective mutant strains. Mice 
were infected intraperitoneally (i.p.) with 200 tachyzoites of WT RH or RH:Δcdpk2 strain, or 
with 105 tachyzoites of WT Pru or Pru:Δcdpk2 strain. In addition to separate curves that show 
the difference in the survival rate between WT RH and Pru strains and their corresponding 
mutant strains (A–D), the overall survival rates in all infected mouse groups were combined in 
one graph (E). 
 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy211/4969761
by guest
on 17 April 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy211/4969761
by guest
on 17 April 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
Figure 6. 
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Figure 7. 
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